Nerandomilast

Vicore Pharma presented promising Phase 2a trial data at the 2025 ATS Conference showing buloxibutid significantly improved lung function in idiopathic pulmonary fibrosis patients compared to existing treatments.

Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions.

Boehringer Ingelheim and Cue Biopharma have formed a strategic partnership to develop CUE-501, a first-in-class bispecific therapy designed to selectively deplete disease-causing B cells in autoimmune conditions.

Boehringer Ingelheim reached 66 million patients in 2024, an 8% increase from the previous year, while investing €6.2 billion (23.2% of net sales) in research and development.

Boehringer Ingelheim initiates LENTICLAIR 1 Phase I/II trial evaluating BI 3720931, a novel inhaled gene therapy targeting cystic fibrosis using Oxford Biomedica's lentiviral vector technology.